<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1514">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087162</url>
  </required_header>
  <id_info>
    <org_study_id>Psiriwat</org_study_id>
    <nct_id>NCT03087162</nct_id>
  </id_info>
  <brief_title>Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori</brief_title>
  <official_title>Once Daily Dose Dexlansoprazole Levofloxacin Based Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramathibodi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ramathibodi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      New drug regimen for Helicobacter pylori eradication, the investigators compare once daily
      dose dexlansoprazole levofloxacin based quadruple therapy and twice daily dose
      dexlansoprazole levofloxacin quadruple therapy for helicobacter pylori eradication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once daily dose dexlansoprazole should be non inferior to twice daily dose in the
      eradication of Helicobacter pylori infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate (percentage)</measure>
    <time_frame>Jan17-Nov17, Total 11 months</time_frame>
    <description>Compare eradication rate of helicobacter pylori between 2 groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare drug compliance</measure>
    <time_frame>jan17-Nov17, Total 11 months</time_frame>
    <description>The investigators measure drug compliance between 2 groups, The investigators consider more than 85% of taking medications is a good compliance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare drug adverse event</measure>
    <time_frame>jan17-Nov17, Total 11 months</time_frame>
    <description>The investigators measure adverse events as
Nausea/Vomiting
Abdominal pain/Abdominal discomfort/Abdominal Bloating
Diarrhea/ Constipation
Taste distortions
Headache/Dizziness
Rash/Itching/Drug allergy, Any symptoms occur new onset during taking medications, The investigators consider as an adverse events of an experiment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>H Pylori Eradication</condition>
  <arm_group>
    <arm_group_label>Once daily dose dexlansoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 Dexlansoprazole 60 mg by oral once daily for 14 days (Levofloxacin 500 mg by oral once daily for 14 days Amoxicillin 1000 mg by oral bid for 14 days Bismuth 1048 mg by oral bid for 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice daily dose dexlansoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 Dexlansoprazole 60 mg oral bid 14 Days (Levofloxacin 500 mg od oral 14 Days Amoxicillin 1000 mg bid oral 14 Days Bismuth 1048 mg bid oral 14 Days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexlansoprazole 60 mg once daily</intervention_name>
    <description>Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm</description>
    <arm_group_label>Once daily dose dexlansoprazole</arm_group_label>
    <arm_group_label>Twice daily dose dexlansoprazole</arm_group_label>
    <other_name>dexilant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 year-patient

          2. Diagnosed as positive Helicobacter Pylori testing by any of the following methods:

               -  Rapid urease test or Histology

          3. Inform consent

        Exclusion Criteria:

          1. Previous history of Helicobacter pylori eradication

          2. Contraindications or allergic reactions to the study drugs

          3. Previous gastric surgery or advanced gastric cancer or other malignancy or other
             severe concurrent diseases

          4. Decompensated Liver cirrhosis or chronic kidney disease (GFR&lt; 30)

          5. Mental disorders or alcohol or drug addiction

          6. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akrawit Pulsombat, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Ramathibodi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parin Siriwat, Doctor</last_name>
    <phone>66825466222</phone>
    <email>Pangmyg@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parin siriwat</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parin Siriwat, Doctor</last_name>
      <phone>66825466222</phone>
      <email>pangmyg@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Akarawit pulsombat, Doctor</last_name>
      <phone>6622011387</phone>
      <email>tataera@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>February 9, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ramathibodi Hospital</investigator_affiliation>
    <investigator_full_name>Parin siriwat</investigator_full_name>
    <investigator_title>Fellowship of Gastroenterology Unit, Ramathibodi Hospital</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
